Considering the increasing rates of childhood obesity under 12 years of age, expanding the use of GLP-1 agonists to younger children could be seen as a potential intervention strategy to halt this serious risk factor for several metabolic syndromes in adulthood. This evidence concerns the gene GLP1R and metabolic syndrome.